<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898014</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574195</org_study_id>
    <secondary_id>CLCC-IC-2006-04</secondary_id>
    <secondary_id>INCA-RECF0474</secondary_id>
    <nct_id>NCT00898014</nct_id>
  </id_info>
  <brief_title>Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer</brief_title>
  <official_title>Study Evaluating the Prognostic and Predictive Value of Response to First-Line Chemotherapy by Detection of Circulating Tumor Cells (CTC) in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Measuring blood levels of tumor cells in patients with breast cancer may help&#xD;
      doctors predict how patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at blood levels of tumor cells in predicting&#xD;
      response in patients receiving first-line chemotherapy for stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Predict the overall and progression-free survival of patients with stage IV breast&#xD;
           cancer by measuring the rate of circulating tumor cells (CTC) before the second course&#xD;
           of chemotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Predict overall and progression-free survival of these patients by measuring the rate of&#xD;
           CTC before the start of chemotherapy, at the first tumor evaluation, and after 2-3&#xD;
           courses of chemotherapy.&#xD;
&#xD;
        -  Correlate the detection of CTC with tumor markers, clinical response, and radiological&#xD;
           response.&#xD;
&#xD;
        -  Study the changing status of HER-2 in CTC in patients receiving trastuzmab (Herceptin®).&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Blood samples are collected at baseline, before the second course of chemotherapy, before the&#xD;
      third or fourth course of chemotherapy, and when progressive disease is diagnosed (before&#xD;
      second-line treatment is initiated). Circulating tumor cells from the blood samples are&#xD;
      examined by immunofluorescence.&#xD;
&#xD;
      Patients are followed periodically for up to 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Correlation of circulating tumor cells (CTC) with overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of CTC with progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of circulating tumor cells with tumor markers, clinical response, and radiological response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HER-2 status in patients receiving trastuzumab (Herceptin®)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of stage IV breast cancer&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Scheduled to receive first-line chemotherapy with or without trastuzumab (Herceptin®),&#xD;
             depending on HER-2 status&#xD;
&#xD;
          -  Histologic block available for confirming pathologic diagnosis and measuring HER-2&#xD;
             status via FISH&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  No other cancer in the past 5 years except for basal cell skin cancer or epithelial in&#xD;
             situ cancer of the cervix&#xD;
&#xD;
          -  No geographic, social, or psychiatric reasons that would make treatment impossible&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves Pierga, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

